Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The grant will fund research into more than 50 species of wildlife to better monitor for and prevent biological threats to humans  BOSTON and UNIVERSITY PARK, Pa. , Oct. 24, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced it is joining efforts with Penn State University to integrate its biosurveillance capabilities into the university's research of 58 wildlife species for SARS-CoV-2 to monitor potential spillover to humans.

Concentric by Ginkgo Partners with Penn State University on Zoonotic Disease Biosurveillance Research Supported by USDA Grant

UiPath

Twilio

Twilio's latest installment in AI can help its 300,000 customers bring on an entirely new level of customer engagement. UiPath is well positioned to take advantage of secular trends in AI given its ability to integrate with major cloud players Microsoft, Amazon, and Alphabet.

Hidden Gems: 3 Stealthy AI Stocks Quietly Conquering the 2023 Market

Ginkgo Bioworks boasts an impressive roster of clients, partners, and executives. The company's revenue is unpredictable while its cash burn is hard to ignore.

Cathie Wood Just Doubled Down on This Biotech Stock. Should You Follow Her Lead?

BELGRADE, Serbia and BOSTON , Oct. 19, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Government of Serbia today announced that they have entered into a Memorandum of Understanding ("MoU") with the intent of collaborating in support of Serbia's bioeconomy vision. Under the planned partnership, Ginkgo and the Serbian Ministry of Science, Technological Development and Innovation will work to establish a Startup Accelerator that leverages Ginkgo's horizontal platform and extensive expertise to create and support Serbian companies building with biology.

Government of Serbia and Ginkgo Bioworks Announce Bioeconomy Collaboration in BIO4 Campus

Famous investor Cathie Wood has been buying up shares of Ginkgo Bioworks over the past year. The company's revenue has climbed in recent years, but the share price hasn't followed.

This Cathie Wood Stock Could Soar 140%, Wall Street Says. Is That Too Optimistic?

- Persephone to utilize the Bacteroides technology for the rapid generation of therapeutics from its planned and ongoing biomarker studies, including the ARGONAUT study - Ginkgo retains the rights to leverage the toolkit to address a wide range of customer needs and applications SAN DIEGO and BOSTON , Oct. 17, 2023 /PRNewswire/ -- Persephone Biosciences Inc., a synthetic biology company reimagining patient health through the microbiome, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of their first collaboration together, a Bacteroides engineering toolkit. Under the collaboration, both Persephone and Ginkgo have access to this reusable toolkit.

Persephone Biosciences and Ginkgo Bioworks Complete Reusable Bacteroides Anaerobic Engineering Toolkit

BOSTON , Oct. 16, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Zenfold Sustainable Technologies, a company focused on developing and manufacturing specialty ingredients using sustainable technologies and precision fermentation, today announced a collaboration to leverage Ginkgo Enzyme Services in its effort to discover an enzyme critical to the manufacturing of veterinary products. This partnership aims to replace traditional chemical processes in veterinary active ingredient production with a sustainable biological method.

Zenfold Leverages Ginkgo Enzyme Services to Enable Veterinary Active Ingredient Development with Sustainable Biology

CRISPR Therapeutics

There are a couple of stocks in the healthcare sector that could climb more than 100%, according to consensus estimates from Wall Street analysts. Analysts expecting CRISPR Therapeutics to launch its first drug next year think the stock could more than double from recent prices.

2 Growth Stocks That Could Double Your Money, According to Wall Street

ZURICH, Switzerland and BOSTON , Oct. 12, 2023 /PRNewswire/ -- QL AG, an innovative food technology solutions company, today announced a new collaboration to develop dairy proteins with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. QL AG will tap into Ginkgo's extensive capabilities in strain engineering across multiple chassis organisms to support its goal of providing the market with high-quality nutritionally equivalent dairy proteins.

QL AG Announces Partnership with Ginkgo Bioworks to Develop Dairy Proteins

Caribou Biosciences

Caribou's gene editing technology has delivered positive results so far in its early-stage clinical trials. Ginkgo Bioworks may help top pharma companies make better drugs.

2 Exciting Biotech Stocks to Buy With Less Than $10

Ginkgo Bioworks' stock price has been volatile due to mixed Q2 earnings, partnership announcements, and concerns about the macro environment. Antheia recently achieved a successful full-scale production run of its first product, but it is unclear how involved Ginkgo was in this achievement and whether it stands to benefit. Ginkgo's partnership with Google and the regulatory approval of Light Bio's bioluminescent plants have boosted investor sentiment, despite their uncertain impact on Ginkgo's business.

Ginkgo Bioworks: Products Progressing Towards Market

Eli Lilly

Vertex Pharmaceuticals

While the S&P 500 remains up on the year, the biotech sector is down. Even though the broader market is showing signs of strength in areas like AI and automation, those trends haven't benefited biotech stocks as much.

3 Biotech Stocks Ready to Break Out in 2024

Led by Northeastern University, the EPISTORM center will prepare local communities and hospitals for future outbreaks BOSTON , Oct. 5, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that its biosecurity and public health unit, Concentric by Ginkgo, will partner with Northeastern University, which has received a grant from the Centers of Disease Control and Prevention over the next five years to head an innovation center led by a consortium of organizations designed to help the United States to detect and prepare for the next outbreak of infectious disease. With the CDC's support, Northeastern will lead a nationwide consortium to develop systems to prepare local communities and hospitals across various geographic regions—including rural areas—for outbreaks, according to the university's announcement.

Concentric by Ginkgo to Support CDC-Funded Consortium to Develop New AI-Based Technologies for Epidemic Forecasting

Kratos Defense & Security Solutions

PagerDuty

Although the innovation space may be on the verge of a broader correction, certain ideas may pop higher, which brings us to Cathie Wood stocks to make you rich. One of the most respected names on Wall Street, Wood is the founder of ARK Invest, a global asset manager.

3 Promising Cathie Wood Stocks That Will Make Early Investors Rich

Some analysts and portfolio managers see a bright future for Ginkgo Bioworks. Each collaborator that signs on is a vote of confidence in its future success.

Wall Street Says Ginkgo Bioworks Stock Will Soar 132%, and Cathie Wood's Buying It. Should You?

Medical Properties Trust

Plug Power

Wall Street projections can give investors valuable insight into a stock's potential upside. But those price targets can quickly become outdated.

3 Stocks Wall Street Thinks Can Nearly Double -- and Why They Might Be Dead Wrong

Shockwave Medical

Bio-Techne

Shockwave Medical just got a boost from a Medicare decision on one of its products. Bio-Techne is benefiting from increased cell and gene therapy revenue.

3 Healthcare Stocks to Keep an Eye On

BOSTON and BERLIN , Oct. 2, 2023 /PRNewswire/ -- Nosh.bio, a German startup developing highly functional ingredients from fungal biomass for animal-free food products, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership. Nosh.bio will leverage Ginkgo Strain Optimization Services to screen for protein-producing fungi strains with superior sensorial profiles.

Nosh.bio Leverages Ginkgo Strain Optimization Services to Enhance Meaty Taste of Mycoprotein

The grant will fund research of white-tailed deer to evolve knowledge of spillover events and support efforts to design an early warning system for biological threats BOSTON and COLLEGE STATION, Texas , Sept. 29, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Texas A&M University today announced they have been jointly awarded a research grant from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (USDA APHIS) via the National Institute of Food and Agriculture, Agriculture and Food Research Initiative (NIFA AFRI) to study SARS-CoV-2 in white-tailed deer populations in Texas.

Concentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover

BOSTON , Sept. 28, 2023 /PRNewswire/ -- Ensovi Inc., which has invented an efficient, cell-free biomanufacturing platform that transforms waste CO2 to organic chemicals, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity.

Ensovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing

Ginkgo Bioworks and Pfizer announced a new RNA therapeutics collaboration today. In response, Ginkgo Bioworks' stock jumped by double digits in early-morning trading Wednesday.

Why Ginkgo Bioworks Stock Is Surging Higher Today

NextEra Energy

Smart investors are looking for ways to put their money to work well. NextEra Energy Partners cut its expectations for distribution growth.

These 2 Stocks Are Getting Smart Investors' Attention Wednesday

Pfizer

Ginkgo Bioworks (NYSE: DNA ) stock jumped almost 14% overnight after it signed a collaboration agreement with Pfizer (NYSE: PFE ). The deal gives Ginkgo upfront cash and could eventually be worth $331 million, based on its RNA technology.

DNA Stock Alert: Ginkgo Bioworks Announces Major Partnership With Pfizer

Shares of Ginkgo Bioworks Holdinsg Inc jumped 16% premarket following the announcement of a potentially lucrative tie-up with pharmaceutical giant Pfizer Inc (NYSE:PFE). The partnership aims to leverage Ginkgo's cutting-edge RNA technology to discover and develop novel RNA molecules for "priority research areas".

Ginkgo Bioworks up 16% premarket on the back of $331m Pfizer deal

BOSTON , Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates.

News for Ginkgo Bioworks Holdings Stock (DNA)